Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Lumira Ventures is a prominent life sciences venture capital firm headquartered in Toronto, Canada. Established in 2007 following a management buyout of MDS Capital, Lumira Ventures has carved a niche in the venture capital landscape by focusing on transformative healthcare solutions. The firm has successfully funded over 100 companies and raised more than $6 billion in capital for its portfolio, showcasing its significant impact on the life sciences sector. With a strong presence across North America, including offices in Montreal, Vancouver, and Boston, Lumira Ventures is well-positioned to leverage its extensive network and resources to support innovative companies. The firm is recognized for its commitment to enhancing patient outcomes and addressing unmet clinical needs through strategic investments in therapeutic products and medical devices. Lumira Ventures' reputation is built on its ability to identify and nurture companies that develop impactful healthcare solutions, making it a trusted partner for entrepreneurs in the life sciences domain.
Lumira Ventures specializes in investing in therapeutic products and medical devices that span the entire development continuum, from early-stage therapeutics to late clinical and revenue-generating medical devices. The firm targets a diverse array of therapeutic areas, including oncology, cardiology, and pain management, with a particular emphasis on addressing high unmet clinical needs. By focusing on innovative solutions that enhance patient outcomes and reduce healthcare costs, Lumira Ventures aims to create inclusive healthcare solutions that improve treatment effectiveness. The firm seeks to partner with visionary founders and companies that share its commitment to transforming healthcare through groundbreaking technologies and therapies. With a flexible investment strategy, Lumira Ventures is equipped to support companies at various stages of development, providing not only capital but also strategic guidance and industry expertise to help them succeed in a competitive landscape.
Lumira Ventures boasts a robust portfolio of over 100 companies, with notable investments in transformative life sciences firms. Among its standout portfolio companies is **Endotronix**, a leader in heart failure management solutions, which was acquired by Edwards Lifesciences. Another significant investment is **OpSens Medical**, known for its pioneering fiber optic sensing technology for coronary artery disease, which is set to be acquired by Haemonetics for $345 million. **Bardy** developed a patient-friendly cardiac monitoring solution and was acquired by Hillrom for $375 million. Additionally, **Engage Therapeutics** created the first on-demand treatment for active epileptic seizures, with an acquisition deal valued at up to $270 million by UBC. Other notable companies in Lumira's portfolio include **Aurinia Pharmaceuticals**, which developed the first oral therapy for lupus nephritis, **Zymeworks**, focusing on bi-specific antibodies for cancer treatment, and **G1 Therapeutics**, which develops therapies for oncology, including triple-negative breast cancer. This diverse portfolio underscores Lumira Ventures' commitment to investing in innovative solutions that address critical healthcare challenges.
To pitch Lumira Ventures, founders should visit their website at lumiraventures.com for submission guidelines. The firm is open to pitches from companies that align with their investment focus in life sciences and healthcare. They prefer to receive pitches through their online platform, which allows for a streamlined review process.
Lumira Ventures invests across a wide range of stages, including Pre Seed, Seed, Seed Plus, Series A, Series B, Series C, and Growth Equity. This flexibility allows them to support companies at various points in their development journey.
Founders interested in pitching Lumira Ventures can submit their proposals through their website at lumiraventures.com. The firm welcomes pitches from companies that align with their focus on transformative life sciences solutions.
Lumira Ventures primarily focuses on the biotech and healthcare sectors, investing in therapeutic products and medical devices that address high unmet clinical needs. Their portfolio includes companies in oncology, cardiology, and pain management.
While specific check sizes are not disclosed, Lumira Ventures is known for making substantial investments across various stages, reflecting their commitment to supporting transformative healthcare solutions.
Lumira Ventures has a strong geographic focus on North America, with a presence in Canada and the United States. Their offices in Toronto, Montreal, Vancouver, and Boston enable them to engage with a broad range of innovative companies.
Lumira Ventures actively engages with its portfolio companies, providing not only capital but also strategic guidance and industry expertise. They focus on enhancing patient outcomes and addressing unmet clinical needs through collaborative partnerships.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.